A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study

Trial Profile

A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DUALIS
  • Most Recent Events

    • 05 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 05 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top